These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7947249)

  • 1. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases.
    Wattel E; Cambier N; Caulier MT; Sautière D; Bauters F; Fenaux P
    Br J Haematol; 1994 May; 87(1):205-8. PubMed ID: 7947249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
    Chan G; DiVenuti G; Miller K
    Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
    Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
    Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes.
    Viniou N; Plata E; Terpos E; Variami E; Meletis J; Vaiopoulos G; Loukopoulos D; Chatzidimitriou G; Yataganas X
    Acta Haematol; 2002; 107(4):234-6. PubMed ID: 12053153
    [No Abstract]   [Full Text] [Related]  

  • 5. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy.
    Hebbar M; Kaplan C; Caulier MT; Wattel E; Morel P; Wetterwald M; Bauters F; Fenaux P
    Br J Haematol; 1996 Jul; 94(1):112-5. PubMed ID: 8757517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of danazol in myelodysplastic syndromes.
    Marini B; Bassan R; Barbui T
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1481-9. PubMed ID: 3181270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of 76 patients with myelodysplastic syndromes treated with danazol.
    Chabannon C; Molina L; Pégourié-Bandelier B; Bost M; Léger J; Hollard D
    Cancer; 1994 Jun; 73(12):3073-80. PubMed ID: 8200005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Kang H; Lee KH
    Br J Haematol; 2019 Oct; 187(1):e4-e7. PubMed ID: 31368111
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
    Tsimberidou AM; Giles FJ; Khouri I; Bueso-Ramos C; Pilat S; Thomas DA; Cortes J; Kurzrock R
    Ann Oncol; 2005 Jan; 16(1):139-45. PubMed ID: 15598951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danazol treatment of myelodysplastic syndromes.
    Stadtmauer EA; Cassileth PA; Edelstein M; Abrahm J; Schreiber AD; Nowell PC; Cines DB
    Br J Haematol; 1991 Apr; 77(4):502-8. PubMed ID: 1827346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized study of danazol vs. placebo in myelodysplastic syndromes.
    Avilés A; Rubio ME; Gómez J; Medina ML; González-Llaven J
    Arch Invest Med (Mex); 1989; 20(2):183-8. PubMed ID: 2690768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway.
    Hellström-Lindberg E; Kanter-Lewensohn L; Nichol J; Ost A
    Br J Haematol; 1999 Jun; 105(4):966-73. PubMed ID: 10554808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
    Garcia-Manero G; Scott BL; Cogle CR; Boyd TE; Kambhampati S; Hetzer J; Dong Q; Kumar K; Ukrainskyj SM; Beach CL; Skikne BS
    Leuk Res; 2018 Sep; 72():79-85. PubMed ID: 30114559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
    Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
    Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases.
    Blanco R; Martinez-Taboada VM; Rodriguez-Valverde V; Sanchez-Andrade A; González-Gay MA
    Br J Rheumatol; 1997 Oct; 36(10):1095-9. PubMed ID: 9374927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
    Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
    Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Danazol therapy for cyclic thrombocytopenia.
    Rocha R; Horstman L; Ahn YS; Mylvaganam R; Harrington WJ
    Am J Hematol; 1991 Feb; 36(2):140-3. PubMed ID: 2012064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.